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Intestinal	enteroendocrine	cells	are	critical	to	central	regulation	of	caloric	consumption,	since	they	activate	
hypothalamic	circuits	that	decrease	appetite	and	thereby	restrict	meal	size	by	secreting	hormones	in	response	
to	nutrients	in	the	gut.	Although	guanylyl	cyclase	and	downstream	cGMP	are	essential	regulators	of	centrally	
regulated	feeding	behavior	in	invertebrates,	the	role	of	this	primordial	signaling	mechanism	in	mammalian	
appetite	regulation	has	eluded	definition.	In	intestinal	epithelial	cells,	guanylyl	cyclase	2C	(GUCY2C)	is	a	
transmembrane	receptor	that	makes	cGMP	in	response	to	the	paracrine	hormones	guanylin	and	uroguanylin,	
which	regulate	epithelial	cell	dynamics	along	the	crypt-villus	axis.	Here,	we	show	that	silencing	of	GUCY2C	
in	mice	disrupts	satiation,	resulting	in	hyperphagia	and	subsequent	obesity	and	metabolic	syndrome.	This	
defined	an	appetite-regulating	uroguanylin-GUCY2C	endocrine	axis,	which	we	confirmed	by	showing	that	
nutrient	intake	induces	intestinal	prouroguanylin	secretion	into	the	circulation.	The	prohormone	signal	is	
selectively	decoded	in	the	hypothalamus	by	proteolytic	liberation	of	uroguanylin,	inducing	GUCY2C	signaling	
and	consequent	activation	of	downstream	anorexigenic	pathways.	Thus,	evolutionary	diversification	of	primi-
tive	guanylyl	cyclase	signaling	pathways	allows	GUCY2C	to	coordinate	endocrine	regulation	of	central	food	
acquisition	pathways	with	paracrine	control	of	intestinal	homeostasis.	Moreover,	the	uroguanylin-GUCY2C	
endocrine	axis	may	provide	a	therapeutic	target	to	control	appetite,	obesity,	and	metabolic	syndrome.
Introduction
Body mass reflects central regulation of caloric consumption by 
enteroendocrine cells that sense nutrients in the gastrointestinal 
tract and secrete hormones that activate hypothalamic circuits 
limiting meal size (1). Although guanylyl cyclase and downstream 
cGMP signaling are essential regulators of feeding behavior and 
satiation in invertebrates (2, 3), the role for this primordial sig-
naling mechanism in mammalian appetite regulation remains 
undefined. Guanylyl cyclase 2C (GUCY2C), principally expressed 
in intestinal epithelial cells (4–6), is the receptor for diarrheagenic 
bacterial enterotoxins (STs) (7) and the gut paracrine hormones, 
guanylin (8), and uroguanylin (9). This hormone-receptor system 
constitutes a paracrine tumor suppressing circuit whose dysregu-
lation universally characterizes colorectal carcinogenesis (10, 11). 
Lumenal secretion of the propeptides of uroguanylin (small intes-
tine) and guanylin (colon) stimulates intestinal GUCY2C, regulat-
ing fluid and electrolyte balance (12) and epithelial cell homeostatic 
programs in the gut, organizing the crypt-villus axis (13–15).
Beyond paracrine endolumenal release, these prohormones also 
undergo endocrine secretion by the gut into the circulation (16, 
17). However, in the absence of either cognate receptors mediat-
ing extralumenal responses to these peptides (18, 19) or defined 
homeostatic mechanisms regulating their endocrine secretion 
from the gut (20), the precise physiological significance of the 
GUCY2C endocrine axis remains ambiguous. In the context of 
the central role of the gut-neural axis in controlling nutrient con-
sumption and the importance of guanylyl cyclase activity in central 
control of invertebrate feeding, we explored the role of GUCY2C 
signaling in appetite regulation.
The present study reveals that eliminating GUCY2C expres-
sion in mice disrupts appetite regulation specifically by impairing 
satiation, producing hyperphagia associated with comorbidities, 
including obesity and metabolic syndrome. Corrupted satiation 
circuits reflect the disruption of a previously unrecognized urogua-
nylin-GUCY2C endocrine axis regulating appetite. Indeed, food 
consumption is the first physiological stimulus that induces secre-
tion of prouroguanylin by intestinal epithelial cells into the circu-
lation in mice and humans. This endocrine prohormone signal is 
selectively decoded centrally by specific proteolytic liberation of 
uroguanylin, but not guanylin, unexpectedly activating neuronal 
GUCY2C and downstream anorexigenic pathways. This study sug-
gests that the GUCY2C-hormone axis is at the center of endocrine 
regulation of central appetite mechanisms and paracrine control 
of intestinal epithelial cell homeostasis (14, 15). This intersection 
of mechanisms regulating the acquisition of nutrients centrally 
and the integrity of cells mediating their processing and absorp-
tion in the gut may represent the evolutionary diversification of 
a more primitive guanylyl cyclase signaling pathway, regulating 
feeding behavior and energy homeostasis (2, 3). Importantly, the 
uroguanylin-GUCY2C endocrine axis provides what we believe to 
be a novel target in the emerging therapeutic armamentarium to 
address appetite control and the obesity pandemic (21).
Results
GUCY2C-deficient mice exhibit increased body weight, reflecting excess adi-
posity. Elimination of GUCY2C expression produces mice (Gucy2c–/– 
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mice) resistant to induction of diarrhea by heat-stable ST (22) 
but susceptible to carcinogen and genetic induction of intestinal 
tumorigenesis (13, 14). Interestingly, Gucy2c–/– mice raised on a 
standard low calorie diet (LCD) (Supplemental Table 1; supple-
mental material available online with this article; doi:10.1172/
JCI57925DS1) displayed accelerated growth, with 10.3% ± 0.3% 
(P < 0.001) increased body mass compared with that of congenic 
wild-type C57BL/6 mice (Gucy2c+/+ mice; Figure 1A). Weight dif-
ferences were also produced by moderate calorie diet (MCD; Sup-
plemental Figure 1A) or high calorie diet (HCD; Figure 1B and 
Supplemental Figure 1B), primarily composed of carbohydrates 
or fat, respectively (Supplemental Table 1). The greatest growth 
differential was observed in female mice raised on a HCD (23), for 
which Gucy2c–/– mice were 26.3% ± 1.3% heavier (P < 0.01) than 
Gucy2c+/+ mice (Figure 1B).
Excess weight in Gucy2c–/– mice was associated with greater 
accumulation of adipose mass and with increases in the percent-
age of body weight contributed by fat (adiposity index, Figure 
1C), reflecting growth in visceral and subcutaneous fat compart-
ments (Figure 1D). In contrast, lean body mass and total body 
water were equivalent between genotypes (Figure 1, E and F). 
Hypertrophy of adipose mass in Gucy2c–/– mice was associated 
with hepatic steatosis (Figure 2, A and B) and elevated serum 
leptin (Figure 2C), an adipocyte-derived peptide whose circu-
lating level reflects fat mass. Furthermore, GUCY2C deficiency 
amplified the metabolic syndrome associated with diet-induced 
obesity, including cardiac hypertrophy (Figure 2D), hyperlepti-
nemia (Figure 2, E and F), hyperinsulinemia (Figure 2G), and 
impaired glycemic control (Figure 2H).
GUCY2C-deficient mice exhibit hyperphagia and diminished satiation. 
Gucy2c–/– mice were hyperphagic, independent of sex, dietary nutri-
ents, or dietary caloric content (Figure 3A). In that context, body 
masses of the genotypes were reversibly equalized by pair feeding 
(Figure 3B), with a direct relationship between calories consumed 
and weight gained (Figure 3C). Of significance, differential food con-
sumption between genotypes was amplified by fasting, independent 
of dietary caloric content or nutrient composition (Figure 3D), sug-
gesting impaired satiation. Indeed, fasted and refed Gucy2c–/– mice 
displayed deficient postprandial satiation (Figure 3E), regardless of 
nutrients inducing the satiation response (Figure 3F).
Beyond increased calorie consumption, excess adiposity may 
also reflect differences in digestion, nutrient absorption, and/or 
energy mobilization/expenditure. In the context of the central 
role of dietary fat in obesity (24), lipid digestion was identical 
between genotypes, and triglycerides were unmeasurable (com-
pletely digested), while free fatty acid levels were comparable in 
stool (Figure 4A). Lipid absorption, distribution, and clearance 
also were equivalent with genotypes exhibiting identical serum 
triglyceride kinetics in the absence or presence of tyloxapol 
(Figure 4, B and C), which inhibits lipoprotein lipase-mediated 
triglyceride uptake by peripheral tissues (25). Additionally, the 
transcripts of rate-limiting proteins mediating lipid absorption 
(Fabp2), glucose absorption (Glut2, Sglt1), fatty acid and triglycer-
ide synthesis (Fasn, Dgat1, Dgat2), and fatty acid oxidation (Acadm, 
Acadl) were equally expressed in intestines of the genotypes (Fig-
ure 4D). Further, energy mobilization and expenditure were 
equivalent, with genotypes exhibiting identical circadian activity 
cycles (Figure 4E) and thermoregulatory reflexes to a cold (4°C) 
Figure 1
Gucy2c–/– mice exhibit increased body weight, reflecting excess adiposity. (A) Growth curves of male Gucy2c+/+ and Gucy2c–/– mice raised on LCD 
(n = 20; P < 0.001). (B) Growth curves of female Gucy2c+/+ and Gucy2c–/– mice raised on HCD (n = 20–40; P < 0.01). (C) Adiposity index (percent-
age body fat) of 12-month-old mice (n = 10–13 per group). (D) Visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and total adipose 
tissue of 12-month-old mice (n = 10–13 per group). (E) Quantification of lean body mass of 12-month-old mice raised on LCD or HCD (n = 10–13 
per group). (F) Total body water content of mice determined by 72 hours desiccation at 90°C (n = 6). All data are mean ± SEM. ***P < 0.001.
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environment (ref. 26 and Figure 4F). Thus, differences in these 
other adipogenic systems were not observed between the geno-
types, establishing increased calorie consumption as the cause of 
the excess adiposity observed in Gucy2c–/– mice.
Systemic administration of GUCY2C ligands induces satiation. Elimi-
nating GUCY2C expression did not disrupt established gut-neural 
axes regulating feeding, and enteroendocrine cell number (15) as 
well as their expression and secretion of intestinal anorexigenic 
peptides were equivalent in Gucy2c+/+ and Gucy2c–/– mice (Supple-
mental Figure 2, A and B). Similarly, gastric emptying and gastro-
intestinal transit were identical between genotypes (Supplemental 
Figure 2C). Surprisingly, activation of intestinal GUCY2C by orally 
administered ST, a proteolytically resistant receptor superagonist 
(27, 28), did not alter food consumption in Gucy2c+/+ mice (Fig-
ure 5A), eliminating a role for endolumenal GUCY2C in signaling 
mechanisms regulating appetite. In contrast, i.v. administration 
of ST induced satiation in Gucy2c+/+ mice (Figure 5B), but not 
Gucy2c–/– mice (Figure 5C), in a dose-dependent fashion (Figure 
5D). Repeated administration of ST to mice with free access to 
food produced durable reductions in food consumption (Figure 
5E). Insensitivity of Gucy2c–/– mice to the anorexigenic effects of 
ST was specific, as peptide YY (PYY) (Figure 5F) and cholecysto-
kinin (CCK) (Supplemental Figure 2D) induced satiation compa-
rably in both genotypes. Anorexigenic effects of systemic ST were 
quantitatively similar to those of PYY (Figure 5G), with a duration 
of action (2 hours) identical to those of glucagon-like peptide-1 
(GLP-1), oxyntomodulin, and PYY (29–31).
GUCY2C expression in hypothalamus. Integration of neurohor-
monal signals regulating appetite occurs in the hypothalamus. 
Beyond intestine, Gucy2c mRNA was expressed in hypothalamus 
but not in extrahypothalamic brain segments or extraintestinal 
tissues (Figure 6A). The full-length coding sequence of Gucy2c, 
amplified from hypothalamic cDNA (Figure 6B), was identical 
to the reported sequence (NM_001127318.1; NCBI Reference 
Sequence). GUCY2C protein was identified in hypothalamus 
(Figure 6, C and D), and ST stimulated guanylyl cyclase activa-
tion and cGMP production in hypothalamic membranes (Figure 
6E). Further, central administration of ST directly into the third 
ventricle reduced feeding, which was quantitatively similar to the 
anorexigenic effect produced by exendin-4 (Figure 6F), a GLP-1 
agonist that decreases feeding after i.c.v. administration (32). Gut 
hormones regulate appetite, in part, by modulating hypothalamic 
neuropeptide transcription, balancing the anorexigenic neuropep-
tide, proopiomelanocortin (Pomc), and the orexigenic neuropep-
tides, agouti-related peptide (Agrp) and neuropeptide Y (Npy) (33, 
34). Hypothalamic expression of these peptides was comparable 
Figure 2
GUCY2C deficiency exacerbates metabolic disease. (A) Liver triglyceride content of 12-month-old mice raised on LCD (n = 19). (B) H&E staining 
of representative left liver lobe sections of 12-month-old mice raised on LCD (scale bar: 200 μM). (C) Mean fasted serum leptin concentrations of 
mice raised on LCD (n = 6–10 per group). (D) Mean heart size (wet weight) of 12-month-old mice raised on LCD or HCD (n = 10–13 per group). 
(E) Mean fasted serum leptin concentrations of 12-month-old mice raised on HCD (n = 10). (F) Correlation of fasted serum leptin level and body 
weight of 12-month-old mice raised on HCD (r2 = 0.47, P < 0.01). The diagonal line represents a linear regression model. (G) Mean fasted serum 
insulin concentrations of 12-month-old mice raised on HCD (n = 10). (H) Glucose tolerance test of fasted 12-month-old mice raised on HCD 
injected i.p. with glucose (2.5 mg/g) (n = 6). All data are mean ± SEM. NS = P > 0.05. *P < 0.05, **P < 0.01.
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in fasted Gucy2c+/+ and Gucy2c–/– mice (Supplemental Figure 3A). 
However, i.v. administration of ST selectively induced expression 
of Pomc mRNA without altering Npy or Agrp transcription (Fig-
ure 6G), providing evidence in hypothalamus of GUCY2C acti-
vation by ST administration. Moreover, these data suggest that 
the anorexigenic neuropeptide, POMC, may be one downstream 
mediator of appetite suppression by GUCY2C.
Food stimulates intestinal prouroguanylin secretion, inducing satiation. 
The hypothalamus is devoid of the endogenous GUCY2C cognate 
ligands, Guca2a (guanylin) and Guca2b (uroguanylin) (Supple-
mental Figure 3B), consistent with endocrine, rather than para-
crine, regulation of GUCY2C. These hormones are secreted into 
the circulation by the intestine as inactive propeptides (16, 17), 
which require proteolytic hydrolysis to liberate C-terminal active 
peptides. Prouroguanylin, but not proguanylin, induced satiation 
in mice (Figure 7A), reflecting hypothalamic decoding of these 
endocrine signals through hormone-specific proteolytic activation 
(Figure 7B). Hypothalamic activation of prouroguanylin mim-
icked that produced by pancreas (Supplemental Figure 3C), the 
principle source of proteolytic liberation of uroguanylin in duode-
num (35). Importantly, nutrient consumption induced endocrine 
secretion of prouroguanylin in mice and humans (Figure 7, C and 
D), with kinetics precisely corresponding to those of satiation (Fig-
ure 7C). Moreover, i.v. administration of prouroguanylin-neutral-
Figure 3
GUCY2C-deficient mice exhibit hyperphagia and diminished satiation. (A) Daily food consumption of 3-month-old female and male mice fed 
MCD or HCD. Points represent the mean of 10 daily food intake measurements (n = 10 per group). (B) Growth of female mice pair-fed HCD 
(2.3 g/mouse/d) (n = 12). (C) Correlation of mean daily food intake and weight gain of 4-month-old mice fed HCD during a 10-day period 
(r2 = 0.72, P < 0.001) (n = 10 per group). The diagonal line represents a linear regression model. (D) Twenty-four–hour food intake of fasted 3- to 
4-month-old female and male mice refed MCD or HCD (n = 10–20 per group). (E) Cumulative food intake of 3- to 4-month-old fasted mice refed 
HCD (n = 10 per group). (F) Two-hour food consumption of fasted mice gavaged with an isovolumetric bolus (300 μl) of water, olive oil, or 35% 
glucose (n = 5 per group). All data are mean ± SEM. Horizontal bars represent mean values. Scattergram points represent data for individual 
mice. *P < 0.05, **P < 0.01, ***P < 0.001.
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izing antibodies blocked nutrient-induced satiation (Figure 7E), 
confirming the role of extraintestinal endocrine GUCY2C signal-
ing in the regulation of appetite.
Discussion
One essential element contributing to body mass homeostasis is 
the regulation of appetite orchestrated by endocrine cells sens-
ing nutrient content in the gastrointestinal tract, which activate 
central anorexigenic circuits. In that context, nutrient-induced 
intestinal prouroguanylin endocrine secretion stimulating cen-
tral GUCY2C, downstream anorexigenic pathways, and satiation 
provides unexpected insight into GUCY2C physiology. GUCY2C, a 
receptor principally expressed in intestinal epithelial cells (4–6), has 
been without a definitive role outside the gut. Further, while intes-
tinal GUCY2C prohormones are secreted both paracrinally, regu-
lating lumenal GUCY2C, and endocrinally, the absence of discreet 
stimuli inducing their secretion and defined extraintestinal recep-
tors mediating their signaling has left the (patho)physiological sig-
nificance of the GUCY2C endocrine axis ambiguous. Here, for the 
first time to our knowledge, the essential elements of a GUCY2C 
endocrine axis have been revealed: (a) a physiological stimulus 
(nutrient ingestion) inducing secretion of prouroguanylin into the 
circulation, (b) an extraintestinal GUCY2C target, and (c) a down-
stream consequence of endocrine hormone-receptor engagement 
(satiation). Moreover, signal discrimination by one receptor that 
binds two paracrine hormones in intestine is achieved spatially by 
compartmentalization, with uroguanylin and guanylin primarily 
expressed in small intestine and colon, respectively. In contrast, 
endocrine signals by these hormones are decoded for a single class 
of receptors outside the intestine by differential proteolytic pro-
cessing of prohormones at the target organ.
For what we believe to be the first time, this GUCY2C endo-
crine axis mediating satiation extends evolutionarily conserved 
primitive cGMP-dependent circuits regulating feeding behavior 
across the phylogenetic continuum to mammals (2, 3). Signaling 
programs mediated by cGMP regulate food acquisition, feeding, 
and satiation across diverse taxa, including worms, flies, bees, and 
ants (3). In Drosophila, cGMP signaling inhibits nutrient consump-
tion, particularly following brief periods of starvation, an analog 
of enhanced satiety (3). Similarly, in Caenorhabditis elegans cGMP is 
a key mediator of quiescence, the cessation of food intake that is 
the homolog of satiation in mammals (2). In that context, quies-
cence in C. elegans is specifically mediated by a membrane-bound 
guanylyl cyclase expressed in select neurons that control feeding 
(2). Moreover, elimination of cGMP signaling in C. elegans pro-
duces loss of appetite regulation and quiescence, excess consump-
tion of nutrients, and accumulation of fat (2). This phenotype 
in worms precisely recapitulates excess nutrient consumption, 
blunting of satiation, and the resultant obesity in mice produced 
by eliminating GUCY2C, a membrane-bound guanylyl cyclase. 
Evolutionary conservation of these pathways broadly across the 
phylogenetic tree highlights the robust solution offered by cGMP 
signaling to the essential challenge of regulating nutrient acquisi-
tion in multicellular organisms (3).
Figure 4
GUCY2C-deficient mice do not display increased lipid absorption efficiency or decreased activity/metabolic rate. (A) Free fatty acid content of 
feces of 3- to 4-month-old mice raised on HCD (n = 16). Scattergram points represent data for individual mice. (B and C) Serum triglyceride 
concentrations of fasted mice with or without tyloxapol (0.75 mg/g) after olive oil gavage (1.5 mg/g) (n = 5). (D) Levels of expression of meta-
bolic genes in intestine, determined by qRT-PCR, normalized to Vil1 expression (n = 4–5 per group). (E) Daily activity patterns of Gucy2c+/+ 
and Gucy2c–/– mice (n = 6). (F) Core body temperatures of mice exposed to a 4°C environment for 24 hours (n = 6). All data are mean ± SEM. 
Horizontal bars represent mean values.
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Satiation mediated by the GUCY2C hormone axis establishes 
what we believe to be the first endocrine role for this receptor 
in (patho)physiology. Originally isolated as a specific product 
of intestinal epithelial cells, GUCY2C was first identified as the 
receptor for bacterial heat-stable STs that induce diarrhea through 
cGMP-dependent regulation of fluid and electrolyte secretion (7). 
Identification of endogenous peptides structurally homologous 
to STs, including uroguanylin and guanylin in the small intes-
tine and colon, respectively, revealed a dichotomous function 
for components of this system (36). These hormones are secreted 
lumenally in intestine in a paracrine fashion, regulating intesti-
nal fluid and electrolyte secretion, a function homologous to STs. 
Moreover, GUCY2C and its paracrine hormone ligands regulate 
epithelial cell homeostatic processes organizing the crypt-surface 
axis, including the cell cycle and proliferation, metabolism, DNA 
damage sensing and repair, and differentiation (13–15, 37).
Beyond these established paracrine functions, guanylin and 
uroguanylin propeptides are secreted from intestine directly into 
the circulation (36, 38). However, the precise endocrine physiol-
ogy mediated by these secreted peptides has remained incom-
pletely defined. This uncertainty is underscored by the absence 
of established physiological stimuli inducing hormone secretion, 
receptors outside the intestine mediating downstream signaling 
by circulating hormones, or discreet responses produced by circu-
lating peptides. An early hypothesis suggested that these peptides 
formed one link in a gut-renal endocrine axis, coordinating sys-
temic fluid and electrolyte balance (36, 38). However, while oral 
and i.v. salt challenge increase local paracrine release of these pep-
tides in gut and kidney, respectively, neither increase circulating 
hormone levels (20, 39). Also, these peptides alter renal fluid and 
electrolyte secretion in the absence of GUCY2C expression (18). 
Further, eliminating uroguanylin, but not GUCY2C, expression 
produces hypertension in mice (40). Moreover, while the evidence 
base has been ambiguous, recent studies have confirmed the 
absence of GUCY2C expression in kidney in placental mammals 
(41). Taken together, these observations demonstrate that renal 
effects of these peptides are mediated by paracrine signaling that is 
independent of GUCY2C and cGMP. By contrast, they underscore 
the role of GUCY2C in endocrine regulation of appetite, in which 
a discreet physiologic stimulus, food ingestion, induces secretion 
of hormone into the circulation targeting GUCY2C in hypothala-
mus, producing satiation.
The obesity pandemic has emerged as one of the greatest glob-
al public health threats, affecting more than 300 million adults 
worldwide (21). Beyond disturbances of body mass, comorbidities 
directly attributable to obesity, including endocrine, metabolic, 
and oncologic diseases, decrease patient life expectancy, with an 
associated economic burden exceeding $100 billion each year in 
the US (42). Deconvoluting gut-brain endocrine axes regulating 
appetite and nutrient consumption is one principal focus for 
developing effective pharmacotherapies that control obesity and 
metabolic diseases (43). Studies here reveal a GUCY2C endocrine 
Figure 5
Systemic administration of GUCY2C ligand induces satiation. (A) Cumulative food intake of fasted Gucy2c+/+ mice orally gavaged with 1 μg ST 
or the inactive alanine-substituted ST analogue, TJU, and refed HCD (n = 10 per group). (B) Cumulative food intake of fasted Gucy2c+/+ mice 
injected i.v. with 1 μg ST or TJU and refed HCD (n = 10 per group). (C) Two-hour food intake of fasted Gucy2c+/+ and Gucy2c–/– mice injected 
i.v. with 1 μg TJU or ST and refed HCD (n = 10 per group). (D) Cumulative food intake of fasted Gucy2c+/+ mice injected with TJU (1 μg) or ST 
and refed HCD (n = 10 per group). (E) Twelve-hour food intake of nonfasted Gucy2c+/+ mice fed HCD and injected with 1 μg TJU or ST every 
3 hours (n = 10 per group). (F) Two-hour food intake of fasted Gucy2c+/+ and Gucy2c–/– mice injected i.v. with TJU (1 μg) or PYY (3 μg) and refed 
HCD (n = 10 per group). (G) Two-hour food intake of fasted Gucy2c+/+ mice injected i.v. with TJU (1 μg), ST (1 μg), or PYY (3 μg) and refed HCD 
(n = 10 per group). All data are mean ± SEM. **P < 0.01, ***P < 0.001.
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circuit controlling appetite. While the impact of loss of GUCY2C 
signaling on body weight is smaller than that in other genetic mod-
els of obesity, such as leptin-deficient ob/ob mice, this likely reflects 
the combined effects of this hormone on both appetite and metab-
olism (44, 45), in contrast to the uroguanylin-GUCY2C system, 
which appears to exclusively regulate appetite. Also, studies here 
do not eliminate the possibility of secondary effects of GUCY2C 
ligands on physiological or behavioral systems that indirectly 
impact appetite. Nevertheless, the present observations provide a 
unique opportunity to probe this pathway and its dysregulation 
as a possible pathophysiologic mechanism contributing to obesity 
and metabolic disease. Moreover, this mechanism could serve as a 
previously unrecognized therapeutic target for the management 
of weight and metabolic disease. Beyond direct GUCY2C ligand 
supplementation, therapeutic strategies could define mechanisms 
mediating intestinal release of prouroguanylin and associated oral 
secretagogues that elevate circulating hormone levels. Also, pro-
teolytic pathways mediating clearance of these peptides from the 
circulation could be defined and inhibited to enhance effective 
circulating concentrations of hormone. Furthermore, unique to 
the uroguanylin-GUCY2C system is the proteolytic activation of 
the propeptide at the target site. Induction of this proteolytic sys-
tem may increase the quantity of active uroguanylin at the hypo-
thalamus and thus increase satiation. The potential for developing 
therapies targeted to this pathway is underscored by the recent 
advance of GUCY2C ligands into late-stage therapeutic trials for 
irritable bowel syndrome and chronic constipation (46).
Loss of GUCY2C paracrine hormone expression is a universal 
early event in colonic neoplasia, disrupting normal epithelial cell 
homeostasis, which potentiates tumorigenesis (11, 37, 47–49). The 
present study reveals the coincidence of body mass regulation and 
tumor suppression by a single hormone receptor system. In that 
context, it is tempting to speculate that the GUCY2C hormone 
axis could contribute to the well-established relationship between 
obesity and colorectal cancer (50). In this model, a deficiency of 
intestinal GUCY2C hormones lies at the pathophysiologic inter-
section of these diseases. Thus, a deficiency in intestinal paracrine 
signaling contributes to tumorigenesis through corruption of 
epithelial homeostasis, while a deficiency in intestinal endocrine 
signaling promotes hyperphagia and obesity. The intriguing cor-
relative hypothesis suggests that paracrine and endocrine supple-
mentation of GUCY2C ligands might benefit obese patients at risk 
for colorectal cancer by coordinately restoring epithelial homeo-
stasis and suppressing appetite, reversing obesity. These consider-
Figure 6
GUCY2C expression in hypothalamus. (A) Gucy2c expression in tissues of Gucy2c+/+ mice, normalized to β-actin (Actb) expression (n = 4–6). 
The inset shows a representative gel image of the Gucy2c qRT-PCR products. (B) PCR products of the coding sequence of Gucy2c from cDNA 
prepared from Gucy2c+/+ mouse tissues. Int, intestine; Hyp, hypothalamus; Lu, lung; Kid, kidney; Spl, spleen; NTC, nontemplate control. (C) 
Representative immunoblot of intestine and hypothalamic GUCY2C. (D) Intestine and hypothalamic GUCY2C protein content determined by 
immunoblot analyses (n = 3). (E) Guanylyl cyclase activity of membrane preparations with or without 1 μM ST (n = 4). (F) Two-hour food intake 
of fasted Gucy2c+/+ mice after administration of TJU (10 μg), ST (10 μg), or exendin-4 (1 μg) into the third ventricle and refed HCD (n = 3 per 
group). (G) Hypothalamic expression of appetite-regulating neuropeptides, normalized to Actb expression, in fasted Gucy2c+/+ mice injected i.v. 
with 1 μg TJU or ST every 2 hours for 8 hours (n = 8). All data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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ations underscore the significance of further exploring the patho-
physiological role of the GUCY2C hormone axes in mechanisms 
underlying colorectal cancer and obesity.
Beyond regulating fluid and electrolyte balance and epithelial 
dynamics in intestine, GUCY2C mediates an extraintestinal endo-
crine axis controlling satiation. This role for GUCY2C signaling 
in modulating appetite provides a previously missing evolution-
ary link between primordial and mammalian signaling programs 
regulating feeding behavior. In the context of the expanding global 
obesity pandemic and the associated paucity of effective manage-
ment options, the GUCY2C endocrine axis offers what we believe 
to be a novel therapeutic opportunity to regulate appetite, restrict 
nutrient consumption, and defend against obesity.
Methods
Mice. Gucy2c–/– mice were generated by the insertion of a neomycin cassette 
into exon 1 and subsequent homologous recombination with embryonic 
stem cells (22). Gucy2c–/– mice were backcrossed with C57BL/6 mice for 
more than 10 generations to produce Gucy2c–/– congenic C57BL/6 mice 
and wild-type (Gucy2c+/+) littermates. Colony-bred Gucy2c+/+ mice were used 
for all experiments comparing Gucy2c+/+ and Gucy2c–/– mice. Additional 
8- to 10-week-old C57BL/6 mice were purchased from the National Cancer 
Institute Animal Production Program. C57BL/6 (8- to 10-week-old) mice, 
which were surgically implanted with i.c.v. cannulas into the third ventri-
cle, were obtained from The Jackson Laboratory. Animals were maintained 
in a pathogen-free, temperature-controlled (20°C), and 12-hour-light/dark 
cycle environment, with free access to food and water. All mouse studies 
were conducted under approved protocols and in agreement with the ani-
mal ethical guidelines of the Thomas Jefferson University Institutional 
Animal Care and Use Committee.
Reagents. Reagents used included native ST and the inactive analog 
ST(5–17)Ala,9,17Cys(Acm),5,10 6-14 disulfide (herein referred to as TJU; 
Bachem). CCK and PYY were obtained from Phoenix Pharmaceuticals Inc. 
Prouroguanylin and proguanylin were obtained from BioVendor R&D. 
Exendin-4 was obtained from California Peptide Research Inc. The prou-
roguanylin antiserum (antibody 6910) was provided by Michael Goy (Uni-
versity of North Carolina, Chapel Hill, North Carolina, USA) (51).
Cell lines. BALB/c-derived CT26 colorectal cancer cells were obtained from 
ATCC. This cell line lacks endogenous GUCY2C, established by radiola-
beled ligand binding and quantitative RT-PCR (qRT-PCR) analyses (52). For 
the generation of the stable CT26 cell line expressing GUCY2C, RNA was 
purified from mucosal scrapings of the jejunum of a 3-month-old C57BL/6 
mouse. RT-PCR was performed using Ex-Taq (Takara) to amplify cDNA, 
which was cloned into pENTR/D-TOPO (Invitrogen) and subcloned into 
pMSCV2.2-Puro to generate Gucy2c-pMSCV2.2-Puro. CT26 cells were trans-
duced with retrovirus produced from 293T cells that were transiently trans-
fected with pCL-Ampho (Imgenex) and Gucy2c-pMSCV2.2-Puro, followed 
by selection with 50 μg/ml puromycin (EMD Chemicals) (52).
Growth curves. For generation of the growth curves, mice were placed on low 
calorie Lab Diet Rodent Diet 5010 (Purina Mills), moderate calorie TestDiet 
Rodent Diet 58Y2 (Purina Mills), or high calorie TestDiet Rodent Diet 58Y1 
(Purina Mills) (Supplemental Table 1) at weaning (3 weeks old), and weights 
Figure 7
Food intake stimulates intestinal prouroguanylin secretion inducing central satiation. (A) Cumulative food intake of fasted Gucy2c+/+ mice injected 
i.v. with TJU (10 μg), prouroguanylin (10 μg), or proguanylin (10 μg) and refed HCD (n = 10 per group). (B) cGMP production of CT26-GUCY2C 
cells treated with PBS, prouroguanylin (5 μg), proguanylin (5 μg), hypothalamic protein (350 μg), or combinations for 30 minutes (black bars, pH 
5.5; red bars, pH 8.0; dark red bar, combined data of pH 5.5/8.0) (n = 4–10 per group). (C) Food intake and serum prouroguanylin concentra-
tions of fasted Gucy2c+/+ mice refed HCD (n = 7). (D) Serum prouroguanylin concentrations of human volunteers fasted for 12 hours and fed 
a standardized test meal (Supplemental Table 2) (P < 0.01, mean postprandial [15–150 minutes] level versus fasting [0 minutes] level) (n = 9). 
(E) Food intake of fasted Gucy2c+/+ mice injected with PBS (control) or prouroguanylin antiserum (100 μl, 1:50 dilution) during the 1- to 2-hour 
interval after refeeding (n = 10 per group). All data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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were measured weekly. Visceral adipose tissue, subcutaneous adipose tissue, 
and heart weights were measured by gross dissection and weighing.
Metabolic studies. For studies using blood, mice were anesthetized by iso-
flurane, and blood was collected into EDTA-coated tubes by poking the 
vascular bundle within the submandibular area with a sterile animal lancet 
(Braintree Scientific). Serum leptin and insulin levels of mice fasted over-
night (16 hours) were quantified by ELISA (Crystal Chem). For glucose 
tolerance tests, mice were fasted overnight (16 hours) and injected (i.p.) 
with glucose (2.5 mg/g). An approximately 1-mm segment was amputated 
from the tail, and approximately 5 μl of blood was placed on a glucose test 
strip and quantified using an Accu-Chek Aviva meter system.
Hepatic triglyceride measurements. Lipids were extracted from the liver 
using the Folch method (53, 54). Briefly, a section of the left liver lobe 
of each mouse was weighed and placed in 3 ml of chloroform/methanol 
(2:1), homogenized, and agitated in an orbital shaker at room tempera-
ture. Homogenates were centrifuged at 425 g, and supernatants recov-
ered and washed with 0.2 volumes of 0.9% NaCl solution. After mixing, 
supernatants were centrifuged at 425 g, and the upper aqueous phase was 
aspirated. The lower organic phase containing lipids was dried by vacuum 
centrifugation, pellets were resuspended in isopropanol/triton X (9:1), and 
triglycerides were quantified with a colorimetric Triglyceride Determina-
tion Kit (Sigma-Aldrich).
Fecal fat measurements. Fecal pellets of 3- to 4-month-old mice raised on 
HCD were dried by vacuum centrifugation and weighed, and lipids were 
extracted. Nonesterified free fatty acids were quantified using the colori-
metric HR Series NEFA-HR(2) Kit (Wako Diagnostics).
Serum triglyceride measurements. Mice were fasted overnight (16 hours) 
and anesthetized with isoflurane, and blood was collected for fasting 
measurements. Mice were then gavaged with olive oil (mixture of oleic 
acid, linoleic acid, and linolenic acid; 1.5 mg/g; Fluka) and replaced in 
their cages without food, blood was collected at subsequent time points, 
and serum triglycerides were quantified using a colorimetric Triglyceride 
Determination Kit (Sigma-Aldrich). For experiments measuring serum 
triglyceride accumulation in the absence of peripheral triglyceride uptake, 
mice were injected with tyloxapol (0.75 mg/g; Sigma-Aldrich), and 30 min-
utes later fasting blood was collected. Mice were then gavaged with olive 
oil (1.5 mg/g), blood was collected at subsequent time points, and serum 
triglycerides were quantified.
Activity measurements. Individual mice were placed in a Versamax Animal 
Activity Monitor daily at 13:00 hours, with free access to food and water, 
and activity was monitored until 11:00 hours the following day. Activity 
measurements were conducted within the animal facility in the controlled 
environment described above.
Thermoregulation. Mice were placed at 4°C, and core body temperature 
was recorded using a Physitemp RET-3 mouse rectal probe connected to a 
Physitemp BAT-12 microprobe electronic thermometer.
Food intake studies. Mice were acclimated to individual wire-mesh cages for 
1 week or more. Daily food consumption for each mouse was measured at 
the same time daily for 10 days and averaged. In fasted food intake studies, 
mice were fasted for 16 hours before evaluation.
Pair feeding. Gucy2c+/+ and Gucy2c–/– mice (10-week-old females) raised 
on HCDs were separated into individual cages and fed 2.3 g/mouse/d of 
HCD, the greatest amount ensuring equivalent food intake. Food was 
replaced daily, and body weights were measured weekly. After 10 weeks 
of restricted diet, mice were given ad libitum access to the diet, and body 
weights were measured weekly.
Satiation responses. Mice (3 months old) raised on HCD were acclimated 
for 1 week in wire-mesh cages, fasted overnight, and provided preweighed 
amounts of HCD, and food consumption was measured after refeeding. 
For nutrient-induced satiation (55), 3-month-old mice were gavaged with 
300 μl of dH2O, 35% glucose, or olive oil and provided preweighed amounts 
of HCD (high fat) (dH2O vs. lipid) or MCD (high carbohydrate) (dH2O vs. 
glucose), and consumption was measured for 2 hours after refeeding.
Gut transit time. Gut transit time was quantified (56) in fasted mice by 
administering FITC-labeled dextran (70,000 MW; Sigma-Aldrich) by gavage 
(100 μl of a 5-mg/ml solution prepared in PBS combined with 100 μl olive 
oil) and 10 minutes later harvesting the entire gastrointestinal tract, from 
stomach to rectum. Small intestine was subdivided into 9 equal sections, 
and colon was subdivided into 2 equal sections. The stomach, small intes-
tinal sections, and colon sections were placed in separate tubes containing 
1 ml PBS (5 ml for stomach), segments were opened, and lumenal contents 
were suspended by vortexing. Fluorescence was quantified in a POLARStar 
Optima multiwell fluorescence plate reader (excitation at 485 nm; emis-
sion at 530 nm) (BMG Labtech).
Intestinal and circulating satiety hormone measurements. Epithelia from jeju-
num and ileum were collected, and protein was extracted in M-PER reagent 
(Pierce). Jejunum samples were assayed for CCK, and ileum samples were 
assayed for GLP-1 and PYY by ELISA (Phoenix Pharmaceuticals), and 
results were normalized to total protein. Blood also was collected, and cir-
culating CCK and GLP-1 were quantified by ELISA.
Oral and i.v. peptide-induced satiation. For oral ligand-induced satiation, 
acclimated and fasted mice were gavaged with TJU (control peptide) or ST 
(1 μg in 100 μl PBS) and subsequently provided a HCD, and consumption 
was quantified after refeeding. For i.v. ligand-induced satiation, acclimated 
and fasted mice received i.v. (100 μl) TJU (1–10 μg), ST (1 μg), PYY (3 μg), 
CCK (1 μg), prouroguanylin (10 μg), proguanylin (10 μg), or prourogua-
nylin antiserum (1:50 in PBS). Mice were then provided a HCD, and con-
sumption was quantified after refeeding.
Quantitative real-time PCR. To quantify Gucy2c, satiety hormone receptor 
(Leprb, Cckar, Glp1r, Npy2r), and hypothalamic neuropeptide (Pomc, Npy, 
Agrp) expression, RNA was extracted using the RNeasy Lipid Tissue Mini 
Kit (Qiagen) and subjected to one-step RT-PCR using TaqMan EZ RT-PCR 
Core Reagents and specific primer/probes from TaqMan Gene Expression 
Assays (Applied Biosystems). RT-PCR was conducted using an ABI Prism 
7000 Sequence Detection System (Applied Biosystems). Relative expression 
was calculated with the 2–ΔΔCT method, using β-actin (Actb) as a reference. 
To quantify expression of intestinal metabolic proteins, extracted RNA was 
converted to cDNA using AMV reverse transcriptase (Roche) and p(dt)15. 
The cDNA was subjected to RT-PCR using the SYBR Green PCR Master 
Mix (Applied Biosystems) and specific primer sets (Supplemental Table 3). 
RT-PCR was conducted as above, and relative expression was calculated 
using villin (Vil1) as a reference.
Mouse GUCY2C monoclonal antibody generation. The monoclonal antibody 
(MS20) recognizing mouse GUCY2C was generated by priming Gucy2c–/– 
mice with 1 × 108 IFU GUCY2CECD-AV by i.m. injection. The truncated 
GUCY2C1–430-expressing adenovirus (GUCY2CECD-AV) was generated as 
described previously (52). Three weeks later, mice were boosted i.p. with 
2.5 × 107 CT26-GUCY2CTM cells in an incomplete Freund’s adjuvant. Mice 
were injected with 25 μg purified GUCY2CECD i.v. in PBS 3 days before 
spleen collection. GUCY2CECD protein was purified as described previous-
ly (52). Spleens were collected 26 days after initial priming and fused with 
the mouse myeloma cell line Sp2/0-Ag14 (ATCC) to create hybridomas 
using the ClonaCell-HY Hybridoma Cloning Kit (Stemcell Technolo-
gies). Positive clones were screened by detection of purified GUCY2CECD 
in ELISA (52). After 3 rounds of limiting dilution to ensure stability and 
clonality, the MS20 hybridoma was grown in the BD CELLine Disposable 
Bioreactor (BD Biosciences), and antibody was purified from superna-
tants using a protein G column.
Immunoblot analyses. Membrane proteins were extracted from tissues 
using MEM-PER reagent (Pierce) supplemented with protease inhibitors 
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(Roche). GUCY2C protein expression was quantified by immunoblot anal-
yses using MS20 GUCY2C (20 μg/ml) and GAPDH antibodies (Cell Signal-
ing Technology). Staining intensity of specific GUCY2C bands, quantified 
by densitometry, was normalized to the staining intensity of GAPDH.
Guanylyl cyclase activity. Intestinal mucosal scrapings, hypothalami, and 
kidneys of Gucy2c+/+ mice were homogenized in ice-cold TEED buffer 
(50 mM Tris-HCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 mM PMSF, 
pH 7.5) containing protease and phosphatase inhibitors (Roche). Homo-
genates were centrifuged at 425 g for 10 minutes at 4°C, and supernatants 
were centrifuged at 100,000 g for 60 minutes at 4°C. Pellets were resuspended 
in TEED buffer, and protein concentration was quantified (BCA protein 
assay; Pierce). Guanylyl cyclase activity was quantified by ligand-induced 
cGMP production (57), and cGMP was measured by radioimmunoassay.
GUCY2C ligand-induced cGMP accumulation. Hypothalamus and pancreas 
homogenates were prepared in DMEM (200 μl) and centrifuged at 250 g 
for 5 minutes at 4°C, supernatants were collected, and protein concentra-
tions were quantified (BCA protein assay; Pierce). Prouroguanylin (5 μg) or 
proguanylin (5 μg) were incubated with tissue extracts (3.5 mg protein/ml) 
or DMEM for 1 hour at 37°C (final volume = 100 μl). Digests were then 
brought to a final volume of 220 μl with DMEM plus IBMX (1 mM). Prou-
roguanylin digests were adjusted to a pH of 5.5 and proguanylin digests 
were adjusted to a pH of 8.0, the optima for uroguanylin and guanylin 
binding and activation of GUCY2C, respectively (35). CT26-GUCY2C cells, 
pretreated with IBMX (1 mM), were incubated for 30 minutes with 100 μl 
of each digest. These cells also were treated with DMEM plus IBMX (1 mM) 
(pH 5.5 or 8.0) to quantify basal cGMP production. cGMP production was 
quantified by radioimmunoassay (15).
i.c.v. peptide-induced satiation. Mice, which had a cannula surgically implant-
ed into the third ventricle, were purchased and acclimated for 3 weeks to 
individual cages with wire-mesh floors and HCD. Mice were fasted over-
night and then lightly anesthetized with isoflurane for insertion of injec-
tor cannulae into guide cannulae. TJU (10 μg), ST (10 μg), and exendin-4 
(1 μg), each diluted to a final volume of 5 μl with sterile PBS, were injected 
at a rate of 1 μl/min for 5 minutes using an Ultra Microsyringe Pump and a 
Micro4 Controller (World Precision Instruments Inc.). After peptide admin-
istration, mice were placed into individual cages and provided preweighed 
amounts of HCD, and consumption was quantified after refeeding.
Serum prouroguanylin ELISA. Immunosorbent plates (Nunc) were coated 
with prouroguanylin antiserum (1:1,000). The immunogenic prourogua-
nylin peptide (PALPLDLQPVCASQE) was diluted in SuperBlock T20 PBS 
Blocking Buffer (Pierce) to generate a standard curve (range, 1 μg/ml – 10 
pg/ml; 630 nM – 0.01 nM). Serum samples were diluted in blocking buf-
fer (1:10), and standard solutions and samples were added to the plate. 
Biotinylated immunogenic peptide was diluted to a final concentration of 
1 ng/ml in blocking buffer and added to the plate. Plates were incubated 
for 30 minutes at 37°C and washed, and signals were visualized with strep-
tavidin-HRP (BD Biosciences).
Human prouroguanylin measurements. Human prouroguanylin was mea-
sured in healthy male volunteers (age, 31.7 ± 10.5 years; BMI, 23.0 ± 2.3 
kg/m2) fasted for 12 hours prior to arrival at the investigation center. A 
cannula was inserted into an anticubital vein, and blood was drawn prior 
to receiving the test meal (Supplemental Table 2; 0 minutes) and at time 
points postprandially. All subjects gave written informed consent for the 
study, and approval was obtained from the Thomas Jefferson University 
institutional review board (control no. 10D-154).
Statistics. Lipid- and carbohydrate-induced satiation and GUCY2C 
ligand-induced cGMP accumulation were analyzed by 1-way ANOVA with 
Tukey’s multiple comparisons test. Correlations of leptin–body weight 
and weight gain–food consumption were analyzed by Pearson correlation. 
Animal weight growth curves were analyzed by fitting Weibull models to 
each sex, genotype, and diet combination, using k = 2,000 nonparametric 
bootstrap confidence intervals for inference, to account for the varying 
number of animals available over time in the growth experiments. Food 
intake after prouroguanylin antiserum treatment was analyzed using a 
linear-mixed model of the natural logarithm of food intake, with effects 
for treatment, time, and treatment × time completed. A linear contrast for 
the a priori hypothesis was generated, providing the least-squares mean 
estimate and P value. Mouse and human prouroguanylin secretion was 
analyzed using mixed-effect linear regression with fixed effects for time 
and a random intercept term to account for correlation among repeated 
measurements from the same subject, with censoring for values below the 
limit of quantification. The mean prouroguanylin level at each postpran-
dial time was compared with the mean fasting level. P values were adjusted 
using Hochberg’s method to account for multiple comparisons. Student’s 
t test or Welch’s t test (for tests with unequal intergroup variances) were 
used for all other analyses. All statistical tests were 2 sided, and P values of 
less than 0.05 were considered statistically significant. Statistical analyses 
were completed in SAS v9.2 and GraphPad Prism software.
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